Bausch Health Co. Inc. (NYSE: BHC) reported Q3 EPS of $1.10, $0.16 better than the analyst estimate of $0.94. Revenue for the quarter came in at $2.05 billion versus the consensus estimate of $2.07 billion.

GUIDANCE:

Bausch Health Co. Inc. sees FY2022 revenue of $8-8.17 million, versus prior guidance of $8.05-8.22 million. Full year Adjusted EBITDA (non-GAAP)1 range of $2.99 - $3.09 billion compared with prior guidance of $3.02 - $3.12 billion

For earnings history and earnings-related data on Bausch Health Co. Inc. (BHC) click here.